NEW YORK, NY / ACCESSWIRE / July 29, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Omnicell, Inc. (“Omnicell” or the “Company”) (NASDAQ: OMCL). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Omnicell and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 11, 2019, GlassHouse Research LLC published a report alleging that Omnicell prematurely recognized over $38 million in sales. The report also alleged that new product lines had been pushed onto customers, who were hesitant to purchase more inventory because of implementation issues, and that the Company would need to write off $23 million in obsolete inventory.

On this news, Omnicell’s stock price fell $11.41 per share, or nearly 14%, to close at $75.11 per share on July 11, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 553859

NEW YORK, NY / ACCESSWIRE / July 29, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Diebold Nixdorf, Incorporated (NYSE: DBD)

Lawsuit on behalf of: investors who purchased February 14, 2017 – July 4, 2017
Lead Plaintiff Deadline : September 3, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/diebold-nixdorf-incorporated-loss-form?prid=2660&wire=1

According to the filed complaint, during the class period, Diebold Nixdorf, Incorporated made materially false and/or misleading statements and/or failed to disclose that: (1) as a result of the Wincor acquisition and related integration, the Company was less focused on its core business; (2) the Company expected certain customers would not renew their service contracts (i.e. contract runoff); (3) the Company was not adequately prepared to staff service technicians; (4) as a result of the expected contract runoff, the Company would suffer a shortage of adequately trained service technicians; (5) as a result, the Company would suffer margin pressure in its services segment; (6) as a result of the foregoing, the Company would lose market share; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Fred’s, Inc. (NASDAQGS: FRED)

Lawsuit on behalf of: investors who purchased December 20, 2016 – June 28, 2017
Lead Plaintiff Deadline : August 27, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/freds-inc-loss-form?prid=2660&wire=1

According to the filed complaint, defendants made numerous materially false and misleading statements concerning the level of regulatory risk faced by the Original Merger and the Revised Merger which would ultimately cause the termination of the Fred’s Asset Purchase Agreement. Specifically, Defendants made false and/or misleading statements: (i) downplaying or disputing contrary reports from journalists signaling regulatory turbulence in closing the merger; (ii) representing that inside knowledge of the FTC gave confidence that the deal would close.

Omnicell, Inc. (NASDAQGS: OMCL)

Lawsuit on behalf of: investors who purchased October 25, 2018 – July 11, 2019
Lead Plaintiff Deadline : September 16, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/omnicell-inc-loss-form?prid=2660&wire=1

According to the filed complaint, during the class period, Omnicell, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 553855

NEW YORK, NY / ACCESSWIRE / July 29, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Pivotal Software, Inc. (NYSE: PVTL)

Lawsuit on behalf of: investors who purchased investors who purchased common stock pursuant or traceable to the April 2018 initial public offering and/or Pivotal securities between April 24, 2018 and June 4, 2019.
Lead Plaintiff Deadline : August 19, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/pivotal-software-inc-loss-form?prid=2659&wire=1

According to the filed complaint, (i) Pivotal was facing major problems with its sales execution and a complex technology landscape; (ii) the foregoing headwinds resulted in deferred sales, lengthening sales cycles, and diminished growth as its customers and the industry’s sentiment shifted away from Pivotal’s principal products because the Company’s products were outdated, inadequate, and incompatible with the industry-standard platform; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Cloudera, Inc. (NYSE: CLDR)

Lawsuit on behalf of: investors who purchased April 28, 2017 – June 5, 2019
Lead Plaintiff Deadline : August 6, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cloudera-inc-loss-form?prid=2659&wire=1

According to the filed complaint, during the class period, Cloudera, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Cloudera was finding it increasingly difficult to identify large enterprises interested in adopting the Company’s Hadoop-based platform; (ii) Cloudera needed to expend an increasing amount of capital on sales and marketing activities to generate new revenues, even as new revenue opportunities were diminishing; and (iii) Cloudera had materially diminished sales opportunities and prospects and could not generate annual positive cash flows.

Netflix, Inc. (NASDAQGS: NFLX)

Lawsuit on behalf of: investors who purchased April 17, 2019 – July 17, 2019
Lead Plaintiff Deadline : September 20, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/netflix-inc-loss-form?prid=2659&wire=1

According to the filed complaint, during the class period, Netflix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 553854

TORONTO, ON / ACCESSWIRE / July 29, 2019 / ITOCO INC. (“ITOCO” or the “Company) (OTC Pink: ITMC), announces that it has implemented an enhanced shareholder communications program to bring greater transparency into the Company’s business plans and growth initiatives.

“ITOCO will communicate more effectively with shareholders on an ongoing basis in order to supply pertinent information,” said Michael Paul, CEO of ITOCO. “As the industry is rapidly developing, we thought it prudent to communicate more regularly with our investor base,” added Mr. Paul.

Accurate information about Itoco may be found at www.itoco.net, and through its corporate newsletter. Investors can sign up for the newsletter on the website.

As part of its approach, ITOCO may choose to engage third party brand awareness providers to increase brand visibility and to deliver relevant company information via email, websites or other digital resources through authorized publishers.

On July 26, 2019, the Company became aware of promotional activities from www.OTCexclusive.com that included commentary about Itoco.

Neither the Company nor its officers were involved in the creation or the distribution of the promotional content, nor did the Company have any editorial input or control over the content. While the statements made in the promotional materials are not materially false and/or misleading, they did not originate from the company in any way.

After inquiry of management, the directors, officers, any control persons or controlling shareholders (defined as owning 10% or more of the company’s securities), Itoco has determined that none of the above parties have, directly or indirectly, been involved in any way with the creation, distribution, or payment of promotional materials related to the Company and its security.

“ITOCO will continue to build its brand and execute its diversified business plan in the rapidly expanding cannabis industry. We have been progressing steadily and according to plan,” stated Michael Paul, CEO. “

ABOUT ITOCO INC.

ITOCO’s mission is to be a global leader in processing, distributing, and producing medical cannabis in a compliant environmentally friendly manner.

The ITOCO management team has many years combined experience in business management and execution, raising capital and public company governance.

ITOCO INC. trades on the OTC Markets, symbol: ITMC.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, potential, intends, plans, hopes, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.

CONTACT:

ITOCO
Michael Paul
ir@itoco.net
+1 (905) 829-5000

SOURCE: ITOCO

ReleaseID: 553847

CEDARHURST, NY / ACCESSWIRE / July 29, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Box, Inc. (NYSE: BOX)

Investors Affected : November 28, 2018 – June 3, 2019

A class action has commenced on behalf of certain shareholders in Box, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was unable to close large deals within the quarter; (2) that, as a result, the Company’s revenue would be materially impacted; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/box-inc-loss-submission-form/?id=2658&from=1

Zuora, Inc. (NYSE: ZUO)

Investors Affected : April 12, 2018 – May 30, 2019

A class action has commenced on behalf of certain shareholders in Zuora, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company would focus on implementing RevPro for new customers ahead of the deadline to comply with accounting standard ASC 606; (2) as a result, the Company lacked adequate resources to integrate RevPro with the core business; (3) the Company would focus on RevPro integration a year after the acquisition closed; (4) delays in integrating RevPro would materially impact the business; (5) the market for RevPro was limited to customers seeking to implement new accounting standards such as ASC 606; (6) after the deadline for ASC 606 compliance passed, demand for RevPro was reasonably likely to decline; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/zuora-inc-loss-submission-form/?id=2658&from=1

FedEx Corporation (NYSE: FDX)

Investors Affected : September 19, 2017 – December 18, 2018

A class action has commenced on behalf of certain shareholders in FedEx Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) TNT’s overall package volume growth was slowing as TNT’s large customers permanently took their business to competitors after the Cyberattack; (2) as a result of the customer attrition, TNT was experiencing an increased shift in product mix from higher-margin parcel services to lower-margin freight services; (3) the anticipated costs and timeframe to integrate and restore the TNT network were significantly larger and longer than disclosed; (4) FedEx was not on track to achieve TNT synergy targets; and (5) as a result of these undisclosed negative trends and cost issues, FedEx’s positive statements about TNT’s recovery from the Cyberattack, integration into FedEx’s legacy operations, customer mix, customer service levels, profitability, and prospects lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/fedex-corporation-loss-submission-form/?id=2658&from=1

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

SOURCE: Kuznicki Law PLLC

ReleaseID: 553853

NEW YORK, NY / ACCESSWIRE / July 29, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Pyxus International, Inc. (NYSE: PYX)
Class Period: on behalf of stockholders who purchased Pyxus (f/k/a Alliance One International, Inc. (AOI)) securities between June 7, 2018 and November 8, 2018, inclusive.
Lead Plaintiff Deadline: August 6, 2019

During the class period, Pyxus International, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing longer shipping cycles; (2) as a result, the Company’s financial results would be materially affected; (3) the Company lacked adequate internal control over financial reporting; (4) the Company’s accounting policies were reasonably likely to lead to regulatory scrutiny; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in PYX: http://www.kleinstocklaw.com/pslra-1/pyxus-international-inc-f-k-a-alliance-one-international-inc-loss-submission-form?id=2657&from=1

EQT Corporation (NYSE: EQT)
Class Period: June 19, 2017 to October 24, 2018
Lead Plaintiff Deadline: August 26, 2019

The complaint alleges that during the class period EQT Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) land acquired by the Rice Energy merger was not contiguous with the Company’s previously held acreage, which reduced the purported synergy benefits; (2) the purported longer lateral wells were not feasible because of intervening third-party parcels or prior drilling by EQT, Rice, or third parties; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in EQT: http://www.kleinstocklaw.com/pslra-1/eqt-corporation-loss-submission-form?id=2657&from=1

CannTrust Holdings Inc. (NYSE: CTST)
Class Period: November 14, 2018 to July 12, 2019
Lead Plaintiff Deadline: September 9, 2019

According to filed complaints, CannTrust Holdings Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) the Company’s Pelham greenhouse did not comply with certain regulations; (3) as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in CTST: http://www.kleinstocklaw.com/pslra-1/canntrust-holdings-inc-loss-submission-form?id=2657&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 553852

NEW YORK, NY / ACCESSWIRE / July 29, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Anheuser-Busch Inbev Sa/Nv (NYSE: BUD)

Investors Affected : March 1, 2018 – October 24, 2018

A class action has commenced on behalf of certain shareholders in Anheuser-Busch Inbev Sa/Nv. According to the filed complaint, Defendants issued a steady stream of materially false and misleading reassurances about Anheuser Busch’s deleveraging efforts, cost cutting measures, EBITDA growth, the sufficiency of its liquidity and its debt maturity profile during the Class Period. These positive statements by Defendants created a false impression and materially misled investors about the Company’s finances, including the sustainability of Anheuser-Busch’s dividends. Once Defendants chose to speak about Anheuser-Busch’s finances, they had a duty to speak completely and truthfully, including speaking about those factors that were then having a material adverse effect on the Company’s deleveraging efforts.

Shareholders may find more information at https://securitiesclasslaw.com/securities/anheuser-busch-inbev-sa-nv-loss-submission-form/?id=2656&from=1

Reckitt Benckiser Group plc (OTCMKTS: RBGLY)

Investors Affected : On behalf of all purchasers of Reckitt American Depositary Shares (“ADSs”) from July 28, 2014 through April 9, 2019

A class action has commenced on behalf of certain shareholders in Reckitt Benckiser Group plc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) defendants had engaged in a scheme to artificially inflate the sales of Suboxone Film by more than $3 billion by falsely touting the drug’s purportedly superior efficacy and safety as compared to tablets; (b) contrary to defendants’ public statements, the FDA and internal Company documents had concluded that Suboxone Film posed a potentially greater risk of abuse and child endangerment than other available treatments; (c) defendants had fabricated a safety scare involving Suboxone Tablets in order to unlawfully delay and prevent generic competition; (d) defendants had engaged in a massive marketing campaign that had misrepresented the purported benefits of Suboxone Film as compared to Suboxone Tablets to doctors, healthcare providers, government regulators and investors; (e) defendants had encouraged Suboxone sales through medical providers that they knew were overprescribing the drug, facilitating the drug’s abuse and/or prescribing it in a careless and clinically unwarranted manner, often to hundreds of individuals at a time; (f) as a result of (a)-(e) above, Reckitt’s revenues, net income an d earnings were artificially inflated and the product of illicit business practices; and (g) as a result of (a)-(f) above, Reckitt and Reckitt Pharma were exposed to extraordinary undisclosed legal and reputational risks that could result in billions of dollars in fines, lost business and legal judgments or other monetary penalties.

Shareholders may find more information at https://securitiesclasslaw.com/securities/reckitt-benckiser-group-plc-loss-submission-form/?id=2656&from=1

Karyopharm Therapeutics Inc (NASDAQGS: KPTI)

Investors Affected : on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.

A class action has commenced on behalf of certain shareholders in Karyopharm Therapeutics Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

Shareholders may find more information at https://securitiesclasslaw.com/securities/karyopharm-therapeutics-inc-loss-submission-form/?id=2656&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 553851

NEW YORK, NY / ACCESSWIRE / July 29, 2019 / PerkinElmer, Inc. (United States) (EXCHANGE: PKI) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 29, 2019 at 5:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/C-433070AC1B1DE

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 553637

NEW YORK, NY / ACCESSWIRE / July 29, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Netflix, Inc. (“Netflix” or the “Company”)(NASDAQ: NFLX) of the September 20, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Netflix stock or options between April 17, 2019 and July 17, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/NFLX. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all those who purchased Netflix securities between April 17, 2019 and July 17, 2019 (the “Class Period”). The case, Wallerstein v. Netflix, Inc. et al., No. 19-cv-04195 was filed on July 22, 2019, and has been assigned to Judge Lucy H. Koh.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.

On July 17, 2019, after the market closed, Netflix released a letter to shareholders which revealed that Netflix missed its expected target for number of new subscribers. The letter to shareholders revealed that Netflix lost 126,000 subscribers in the United States during the second quarter of 2019. On the same day, Netflix held an earnings call to discuss its financial and operating results for the quarter. During the call, the Company’s Chief Financial Officer attributed the missed subscription target to the “timing of [Netflix’s] content slate” and price increases.

On this news, Netflix’s share price fell from $362.44 per share on July 17, 2019 to a closing price of $315.10 on July 19, 2019: a $47.34 or a 13.06% two-day drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Netflix’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 553792

NEW YORK, NY / ACCESSWIRE / July 29, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Ra Medical Systems, Inc. (NYSE: RMED)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ra-medical-systems-inc-loss-submission-form?prid=2655&wire=1
Lead Plaintiff Deadline: August 6, 2019
Class Period: stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company’s September 2018 initial public offering.

Allegations against RMED include that: (1) the Company’s evaluation of sales personnel candidates was inadequate; (2) the Company’s training program for sales personnel was inadequate; (3) as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) as a result, the Company would suffer a shortage of qualified sales personnel; (5) the Company’s manufacturing process could not reasonably support increased catheter production; (6) as a result, the Company would suffer production delays; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

L Brands, Inc. (NYSE: LB)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/l-brands-inc-loss-submission-form?prid=2655&wire=1
Lead Plaintiff Deadline: September 23, 2019
Class Period: May 31, 2018 to November 19, 2018

Allegations against LB include that: (a) the Victoria’s Secret and PINK businesses were having a material adverse effect on the Company’s cash flow, liquidity and debt levels; (b) Defendants lacked a reasonable basis for their positive statements about the ability of the Company to sustain its dividend; (c) the MD&A disclosures in filings L Brands made with the SEC were materially false and misleading; (d) the risk factor disclosures in filings L Brands made with the SEC were materially false and misleading; (e) the representations about L Brands’ disclosure controls in filings the Company made with the SEC were materially false and misleading; (f) the certifications issued by Defendants Wexner and Burgdoerfer on L Brands disclosure controls were materially false and misleading; and (g) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about L Brands’ then-current business operations and future financial
prospects.

National General Holdings Corp. (NASDAQGM: NGHC)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/national-general-holdings-corp-loss-submission-form?prid=2655&wire=1
Lead Plaintiff Deadline: September 23, 2019
Class Period: August 6, 2015 to August 9, 2017

Allegations against NGHC include that: (a) National General was perpetrating a massive forced-placed CPI scheme to fraudulently saddle its own customers with unwanted and unneeded automobile insurance policies that it had underwritten; (b) National General’s illicit conduct in foisting unwanted and unneeded automobile insurance on its customers had resulted in some of the victims being declared delinquent, suffering adverse impacts to their creditworthiness, and/or having their cars improperly repossessed; (c) National General was exposed to an extreme risk of regulatory scrutiny, legal risks, and reputational harm as a result of its participation in the forced placed CPI scheme; (d) the Company had failed to maintain effective internal controls over its financial reporting, including by failing to maintain formal documentation sufficient to reasonably ensure the accuracy of internal reporting and accounting procedures across much of its business, including with respect to insurance policy premiums; (e) the Company’s reported quarterly revenues and policy premiums were in part the product of a fraudulent forced-placed insurance scheme and were therefore artificially inflated and unsustainable; and (f) National General had in fact lost substantial business with Wells Fargo because Wells Fargo had terminated the forced-placed CPI scheme after concluding that it posed excessive reputational risk and legal exposure.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 553839